PapersPMID:37671486
A Short-Term Safety Evaluation of Silbinol®- an Extract from Pterocarpus marsupium in Healthy Adults- a Randomized, Double-Blind, Placebo-Controlled Study.
- findings
- 7
- compound
- 1
- endpoints
- 7
- no difference foundSerum potassium concentration
- no difference foundSerum uric acid
- no difference foundSerum creatinine concentration
- no difference foundSerum sodium concentration
- no difference foundAlanine aminotransferase
- no difference foundAspartate aminotransferase
- no difference foundGamma-glutamyl transferase
- Study, every finding
- RCT · 2 months
- Dose studied, every finding
- PME (Silbinol), P. marsupium heartwood extract standardised to 90% pterostilbene, 100 mg capsule twice daily (200 mg/day) after meals
- Population, every finding
- Healthy adults aged 18-49 years (PME n = 29 analysed, placebo n = 30); 60 days
No finding here moved its endpoint.
What did not
How to read these marks →“Renal function parameters like urea, uric acid, creatinine, glomerular filtration rate, sodium, potassium, and chloride levels were comparable between placebo and PME at all time points (Table 4 and Table S5, S6).”
“Parameters of liver function such as total bilirubin, Aspartate transaminase (AST), Alanine transaminase (ALT), and Gamma-glutamyltransferase (GGT) were within the standard reference ranges in subjects supplemented with PME, comparable to the placebo group at the screening, day30 and final visit.”
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Healthy adult volunteers aged 18-49 years, 27 males and 33 females
- Participants
- 60
- Comparator
- placebo
- Duration
- 60 days
- Endpoints measured
- 98